William Wright, MD
Cardiovascular Disease · Bridgeton, MONPI 1962475848
Payments from drug & device makers
Across 479 payments — averaging $43.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$9K
- Abbott$5K
- Boston Scientific$5K
- Cvrx, Inc.$540
- Abiomed$287
- AstraZeneca$263
- plus $2K from 23 others
What the payments were for
- Speaking & faculty fees$500%
- Travel & lodging$6,88633%
- Food & beverage$14,01267%
- Education$450%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 141 | $8,935 |
| Abbott | 81 | $4,633 |
| Boston Scientific | 153 | $4,577 |
| Cvrx, Inc. | 5 | $540 |
| Abiomed | 4 | $287 |
| AstraZeneca | 14 | $263 |
| Novo Nordisk | 12 | $230 |
| Amgen | 10 | $176 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 9 | $166 |
| Merck | 10 | $161 |
| Angiodynamics, Inc. | 1 | $140 |
| Inspire Medical Systems, Inc. | 1 | $121 |
| Novartis | 6 | $97 |
| Cardiac Dimensions, Inc. | 1 | $90 |
| Impulse Dynamics (USA) Inc. | 6 | $83 |
| E.r. Squibb & Sons, L.L.C. | 4 | $70 |
| Pfizer | 3 | $67 |
| Bayer | 3 | $61 |
| Esperion Therapeutics, Inc. | 2 | $52 |
| Scpharmaceuticals Inc. | 2 | $37 |
| Lexicon Pharmaceuticals, Inc. | 2 | $36 |
| Resmed Corp | 1 | $34 |
| Otsuka America Pharmaceutical, Inc. | 2 | $29 |
| Biocompatibles, Inc. | 1 | $24 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $20 |
| Surgenex LLC | 1 | $19 |
| Boehringer Ingelheim | 1 | $16 |
| Philips North America LLC | 1 | $16 |
| Regeneron Healthcare Solutions, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Micra$2,926
- AVEIR$1,996
- GENERAL - THERAPIES$917
- ALLURE$706
- Barostim Neo System$509
- Resolute$248
- COBALT DR MRI SURESCAN$175
- Assurity Pacemaker$142
- Auryon Laser System 100-120 Vac$140
- Impella$140
- ASSURITY$139
- LUX-Dx Insertable Cardiac Monitor$132
- Reveal LINQ$125
- Claria MRI$123
- Inspire$121
- LINQ II$114
- RESONATE$114
- LATITUDE$111
- LUX-DX$109
- GENERAL BRADY$102
How this compares
$20,993 in reported general payments places this provider in the 80th percentile of 391 cardiovascular disease providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 505 | $518,270 |
| EntrestoSacubitril/Valsartan | 40 | $48,094 |
| JardianceEmpagliflozin | 39 | $46,654 |
| XareltoRivaroxaban | 12 | $14,315 |
| BrilintaTicagrelor | 12 | $13,223 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 18 | $5,842 |
| Atorvastatin Calcium | 298 | $3,873 |
| Dofetilide | 28 | $3,567 |
| Metoprolol Succinate | 260 | $3,489 |
| Flecainide Acetate | 58 | $3,240 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 76 | $2,668 |
| SotalolSotalol Hcl | 97 | $2,659 |
| Potassium Chloride | 98 | $2,371 |
| Carvedilol | 264 | $2,073 |
| Ranolazine ErRanolazine | 18 | $1,800 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $67 | $518,270505 claims |
| NovartisEntresto | $97 | $48,09440 claims |
| Boehringer IngelheimJardiance | $16 | $46,65439 claims |
| AstraZenecaBrilinta | $263 | $13,22312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 391 cardiovascular disease providers in Missouri.
Other cardiovascular disease in Bridgeton
- Pradeep ChandraBridgeton$144K
- Elie AzrakBridgeton$140K
- Mikhail KosiborodKansas City$27.8M
- Mohammad TahirSaint Louis$2.7M
- John SpertusKansas City$2.3M
- Joshua MitchellSaint Louis$1.4M
- Nathan StitzielSaint Louis$1.2M
- Daniel KellySaint Louis$1.1M
- Georges ChahoudSaint Louis$967K
- Jiafu OuSaint Louis$853K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.